Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. Bombay Stock Exchange
  5. Gland Pharma Limited
  6. Summary
    543245   INE068V01023

GLAND PHARMA LIMITED

(543245)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Bombay Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
3604.15 3581.8 3619.45 3644.5 3649.25 Last
10981 9003 3471 642253 8096 Volume
+3.01% -0.62% +1.05% +0.69% +0.13% Change
Estimated financial data (e)
Sales 2022 44 498 M 591 M 591 M
Net income 2022 13 113 M 174 M 174 M
Net cash position 2022 22 750 M 302 M 302 M
P/E ratio 2022 45,6x
Yield 2022 0,10%
Sales 2023 55 076 M 732 M 732 M
Net income 2023 16 424 M 218 M 218 M
Net cash position 2023 30 468 M 405 M 405 M
P/E ratio 2023 36,4x
Yield 2023 0,10%
Capitalization 600 B 7 968 M 7 969 M
EV / Sales 2022 13,0x
EV / Sales 2023 10,3x
Nbr of Employees 3 961
Free-Float 31,9%
More Financials
Company
Gland Pharma Limited is an India-based company that manufactures small volume parenterals (SVPs). The Company provides a range of injectables including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions and ophthalmic solutions. It provides contract development and manufacturing services, such as evaluation of development needs, identifying application program interface (API) sources,... 
Sector
Pharmaceuticals
Calendar
01/21Earnings Release
More about the company
Ratings of Gland Pharma Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about GLAND PHARMA LIMITED
11/17Certain Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending..
CI
11/15Indian shares end marginally higher on consumer, pharma boost
RE
11/09Factbox-India's 10 biggest ever IPOs, led by Paytm
RE
10/26Nomura Adjusts Gland Pharma's Price Target to 3,799 Indian Rupees From 3,775 Indian Rup..
MT
10/25GLAND PHARMA : Records Rise in Q2 Consolidated Net Profit, Revenue
MT
10/22Gland Pharma Seeks Acquisition Opportunities
CI
10/22Gland Pharma Limited Reports Earnings Results for the Second Quarter and Six Months End..
CI
10/10GLAND PHARMA : Gets Tentative Nod from US FDA for Sugammadex Injection
MT
10/08Gland Pharma Limited Receives Tentative Approval for Sugammadex Injection
CI
07/23GLAND PHARMA : Nomura Adjusts Gland Pharma's Price Target to 3,775 Indian Rupees From 2,65..
MT
07/21GLAND PHARMA : Consolidated Profit Climbs 12% in Fiscal Q1
MT
07/21Gland Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2021
CI
06/21GLAND PHARMA LIMITED(BSE : 543245) added to S&P Global BMI Index
CI
05/19GLAND PHARMA : Nomura Adjusts Gland Pharma's Price Target to 2,652 Indian Rupees From 2,63..
MT
05/18GLAND PHARMA : Consolidated Profit Jumps in Fiscal Q4
MT
More news
News in other languages on GLAND PHARMA LIMITED
11/15Les actions indiennes terminent en légère hausse grâce à l'essor de la consommation et ..
10/25Gland Pharma enregistre une hausse de son bénéfice net consolidé et de son chiffre d'af..
07/21Le bénéfice consolidé de Gland Pharma a augmenté de 12 % au cours du premier trimestre ..
05/18Le bénéfice consolidé de Gland Pharma bondit au quatrième trimestre fiscal
More news
Analyst Recommendations on GLAND PHARMA LIMITED
More recommendations
Chart GLAND PHARMA LIMITED
Duration : Period :
Gland Pharma Limited Technical Analysis Chart | 543245 | INE068V01023 | MarketScreener
Technical analysis trends GLAND PHARMA LIMITED
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 3 649,25 INR
Average target price 3 988,90 INR
Spread / Average Target 9,31%
EPS Revisions
Managers and Directors
Srinivas Sadu Chief Executive Officer & Managing Director
Ravi Shekhar Mitra Chief Financial Officer
Stanley E. Lau Chairman
K. V. G. K. Raju Chief Technology Officer
C. S. Venkatesan Senior Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
GLAND PHARMA LIMITED55.93%7 968
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641